The Genetic Signatures (ASX: GSS) share price suffers from its lack of profitability, but the diagnostic testing company may be on the verge of substantial growth.

Cogstate (ASX: CGS), Pureprofile (ASX: PPL) and Genetic Signatures (ASX: GSS) each recently updated the market on Q3 FY 2022 results.

The Genetic Signatures (ASX:GSS) share price has dropped almost 10% despite reporting record receipts from customers.

This ASX listed med-tech company has an enterprise value of less than $200m, but has expanded its customer base significantly, as a result of the pandemic.

Pandemomomania – noun – an enthusiasm for stocks that are going up during a pandemic…